Close
ACHEMA MIDDLE EAST 2026

Randomness Drives Tumour Cells Response To Chemotherapy

A new weapon in the arsenal of cancer cells' treatment resistance, according to a study conducted by the Garvan Institute of Medical Research, is...

mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

The FDA has gone on to issue guidance on March 2, 2023 in order to give out recommendations to sponsors that will help in...

Pharma Responds To The Statutory Scheme Surge By The UK

The UK government has gone on to confirm its plans to move ahead with the proposed statutory scheme pharma rate surge. This means that...

Novel Purification Means For Protein Drug Manufacturing

In a recent study, researchers at the Massachusetts Institute of Technology (MIT) have come up with a new purification approach to reduce the cost...

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

One of the most important trade fairs in the pharmaceutical industry will soon be taking place in Japan as it sees a huge resurgence...

Duchenne Muscular Dystrophy-Cancer Genetic Link Discovered

Scientists from the University of Portsmouth have settled on a novel genetic link between Duchenne muscular dystrophy and cancer. Duchenne muscular dystrophy, which happens...

Animal Testing Could See An End With An Artificial Model

Uppsala University researchers have created an artificial blood-brain barrier model that can be used to assess the efficacy of anti-body-based medicines while reducing animal...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...